Enable job alerts via email!
A leading cancer treatment center in Manchester is seeking a Clinical Fellow for a 12-month post in Clinical Oncology. This role involves patient management, research participation, and supervision of Technical Radiotherapy delivery. Ideal candidates will have experience in oncology and expertise in Stereotactic Ablative Body Radiotherapy (SABR). The position requires a commitment to developing clinical skills in one of Europe's largest cancer hospitals.
Applications are welcomed for a 12 month SABR clinical fellow post commencing December 2025 in Clinical Oncology, based at The Christie NHS FT, Manchester, UK Europe’s largest single site cancer hospital.
This post is for 40 hours per week as a Clinical Fellow for the development and implementation of Stereotactic Ablative Body Radiotherapy (SABR) within the organisation for a fixed term period of 12 months with the option to extend for up to a further 12 months. The post holder will be employed by The Christie NHS Foundation Trust and will be based at The Christie. The successful applicant would be expected to work alongside consultants and trainees in out-patient clinics, supervising Technical Radiotherapy delivery and performing on-treatment reviews and follow-up assessments.
The Clinical Oncology establishment currently consists of 59 Consultants who run the clinical service and research practice. There is also a team of 24 SpRs plus Academic and Clinical Fellows.
The appointee will be based at The Christie and will provide senior input to all aspects of the management of patients with HBT and oligometastatic disease. These include (but are not limited to) the screening of referrals, active participation in MDT, assessment of patients, consent, review of patients on pre-treatment, treatment, planning of SABR, review and approval of SABR plans, technical radiotherapy development and post treatment and ePROMS. All of this will be done under the clinical supervision of the designated SABR team consultant.
Advert closes on Friday 10 Oct 2025.